Survival Analysis of 3 Different Age Groups and Prognostic Factors among 402 Patients with Skeletal High-Grade Osteosarcoma. Real World Data from a Single Tertiary Sarcoma Center.
age groups
chemotherapy
local recurrence
metastasis
osteosarcoma
prognosis
survival
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
27 Jan 2021
27 Jan 2021
Historique:
received:
27
12
2020
revised:
19
01
2021
accepted:
23
01
2021
entrez:
30
1
2021
pubmed:
31
1
2021
medline:
31
1
2021
Statut:
epublish
Résumé
Age is a known prognostic factor for many sarcoma subtypes, however in the literature there are limited data on the different risk profiles of different age groups for osteosarcoma survival. This study aims to provide an overview of survival in patients with high-grade osteosarcoma in different age groups and prognostic variables for survival and local control among the entire cohort. In this single center retrospective cohort study, 402 patients with skeletal high-grade osteosarcoma were diagnosed and treated with curative intent between 1978 and 2017 at the Leiden University Medical Center (LUMC). Prognostic factors for survival were analyzed using a Cox proportional hazard model. In this study poor overall survival (OS) and event-free survival (EFS) were associated with increasing age. Age groups, tumor size, poor histopathological response, distant metastasis (DM) at presentation and local recurrence (LR) were important independent prognostic factors influencing OS and EFS. Differences in outcome among different age groups can be partially explained by patient and treatment characteristics.
Identifiants
pubmed: 33513855
pii: cancers13030486
doi: 10.3390/cancers13030486
pmc: PMC7865349
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
BMC Cancer. 2018 May 31;18(1):614
pubmed: 29855362
Pediatr Blood Cancer. 2020 Feb;67(2):e28072
pubmed: 31736201
Sao Paulo Med J. 2019 Sep-Oct;137(5):423-429
pubmed: 31939567
J Clin Oncol. 2002 Feb 1;20(3):776-90
pubmed: 11821461
J Glob Oncol. 2019 Apr;5:1-8
pubmed: 30946633
Cancer. 2009 Apr 1;115(7):1531-43
pubmed: 19197972
Ann Oncol. 2001 Aug;12(8):1145-50
pubmed: 11583198
Eur J Cancer. 2019 Mar;109:36-50
pubmed: 30685685
J Clin Oncol. 2006 Mar 1;24(7):1161-8
pubmed: 16505436
J Investig Med. 2018 Feb;66(2):289-297
pubmed: 28954845
Br J Surg. 1991 Jun;78(6):648-50
pubmed: 2070225
Int Orthop. 2019 Jul;43(7):1741-1747
pubmed: 31011764
J Orthop Sci. 2017 Jul;22(4):749-754
pubmed: 28412026
Clin Sarcoma Res. 2012 Jan 27;2(1):5
pubmed: 22587841
J Cancer Res Clin Oncol. 2010 Apr;136(4):561-70
pubmed: 19784847
Clin Orthop Relat Res. 2004 Dec;(429):286-91
pubmed: 15577500
Clin Orthop Relat Res. 1980 Nov-Dec;(153):106-20
pubmed: 7449206
Eur J Cancer. 2017 Apr;75:98-108
pubmed: 28219023
Cancer. 2019 Oct 15;125(20):3514-3525
pubmed: 31355930
JAMA. 2015 Nov 10;314(18):1966-7
pubmed: 26547468
Ann Oncol. 2015 Feb;26(2):407-14
pubmed: 25421877
Cancer. 2012 Sep 15;118(18):4597-605
pubmed: 22252521
J Clin Oncol. 2016 Sep 1;34(25):3031-8
pubmed: 27400942
Eur J Cancer. 2002 Jun;38(9):1218-25
pubmed: 12044509
Cancer. 1982 Mar 15;49(6):1221-30
pubmed: 6174200
Cancer. 1992 Feb 1;69(3):698-708
pubmed: 1730120
Ann Oncol. 2014 Sep;25 Suppl 3:iii113-23
pubmed: 25210081
Bone. 2011 Dec;49(6):1173-7
pubmed: 21893224
Eur J Cancer. 2001 Jan;37(1):39-46
pubmed: 11165128
Acta Oncol. 2015 Jan;54(1):25-33
pubmed: 24957555
Ann Oncol. 2009 Jun;20(6):1136-41
pubmed: 19153114
Sarcoma. 2014;2014:690316
pubmed: 24723789
Tumori. 2018 Jan-Feb;104(1):30-36
pubmed: 29218692